Beth Israel Deaconess Medical Center in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital and New England Deaconess Hospital.

There are 673 beds in Beth Israel Deaconess - West Campus.

During the past decade, Beth Israel Deaconess - West Campus conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Beth Israel Deaconess - West Campus" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 68 trials, followed by "AIDS Clinical Trials Group" with 2 trials sponsored, "Sandoz" with 2 trials sponsored, "Fisons" with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Beth Israel Deaconess - West Campus" #1 collaborator was "Glaxo Wellcome" with 9 trials as a collaborator, "Bristol-Myers Squibb" with 8 trials as a collaborator, "National Institute of Allergy and Infectious Diseases (NIAID)" with 3 trials as a collaborator, "Hoechst Marion Roussel" with 2 trials as a collaborator and "Hoffmann-La Roche" with 2 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Beth Israel Deaconess - West Campus" are "HIV Infections" (74 trials), "Pneumonia, Pneumocystis Carinii" (7 trials), "Sarcoma, Kaposi" (4 trials), "Mycobacterium Avium-intracellulare Infection" (3 trials) and "AIDS Dementia Complex" (2 trials). Many other conditions were trialed in "Beth Israel Deaconess - West Campus" in a lesser frequency.

Most popular intervention types in "Beth Israel Deaconess - West Campus" are "Drug" (65 trials), "Behavioral" (1 trials), "Biological" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Zidovudine" (27 trials), "Didanosine" (15 trials), "Stavudine" (12 trials), "Indinavir sulfate" (11 trials) and "Lamivudine" (11 trials). Other intervention names were less common.

The vast majority of trials in "Beth Israel Deaconess - West Campus" are 71 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Beth Israel Deaconess - West Campus". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 72 completed trials in Beth Israel Deaconess - West Campus, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Beth Israel Deaconess - West Campus, 10 "Phase 1" clinical trials were conducted, 31 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 7 trials that are defined as “Not Applicable".